NCT07064122 2026-03-02
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
AstraZeneca
Phase 1 Recruiting
AstraZeneca
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Acrivon Therapeutics
AstraZeneca